<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02669121</url>
  </required_header>
  <id_info>
    <org_study_id>NOR-211</org_study_id>
    <secondary_id>U1111-1175-9077</secondary_id>
    <nct_id>NCT02669121</nct_id>
  </id_info>
  <brief_title>Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults</brief_title>
  <official_title>Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Healthy Adults Aged 18 - 49 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of the Norovirus (NoV) GI.1/GII.4&#xD;
      bivalent virus-like particle vaccine against moderate or severe acute gastroenteritis (AGE)&#xD;
      due to genotype-specific (GI.1 and GII.4) NoV strains.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The vaccine being tested in this study is called NoV GI.1/GII.4 bivalent VLP vaccine&#xD;
      adjuvanted with aluminum hydroxide. The norovirus vaccine is being tested to prevent AGE due&#xD;
      to genotype-specific (GI.1 and GII.4) norovirus strains in healthy participants recruited&#xD;
      from a US military training installation. This study will look at the illness rate of AGE&#xD;
      occurring &gt; 7 days after dosing due to genotype-specific (GI.1 or GII.4) NoV strains&#xD;
      represented in the vaccine.&#xD;
&#xD;
      The study will enroll between 2800 and 8700 patients. Participants will be randomly assigned&#xD;
      (by chance, like flipping a coin) to one of the two treatment groups-which will remain&#xD;
      undisclosed to the participant and study doctor during the study (unless there is an urgent&#xD;
      medical need):&#xD;
&#xD;
        -  Norovirus GI.1/GII.4 Bivalent VLP Vaccine&#xD;
&#xD;
        -  Placebo (dummy inactive solution) - this is a liquid that looks similar to the study&#xD;
           drug but has no active ingredient&#xD;
&#xD;
      All participants will receive one dose of study medication on Day 1 administered via&#xD;
      intramuscular injection.&#xD;
&#xD;
      This multi-center trial will be conducted in the United States at select military locations.&#xD;
      The overall time to participate in this study is up to 45 days for participants in the navy&#xD;
      53 days for participants in the Air Force, and 72 days for participants in the marines.&#xD;
      Participants will make multiple visits to the clinic, including a final visit on the last day&#xD;
      of study participation (Day 45, 53 or 72) for a follow-up assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2016</start_date>
  <completion_date type="Actual">June 16, 2018</completion_date>
  <primary_completion_date type="Actual">June 16, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Moderate or Severe Acute Gastroenteritis (AGE) Occurring for &gt;7 Days After Dosing Due to GI.1 or GII.4 Norovirus Strains (Excluding Co-infection)</measure>
    <time_frame>Up to Day 47</time_frame>
    <description>Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by reverse transcriptase polymerase chain reaction (RT-PCR). The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains excluding co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Moderate or Severe AGE Occurring &gt;7 Days After Dosing Due to Any Norovirus Strain (Excluding Co-infection)</measure>
    <time_frame>Up to Day 47</time_frame>
    <description>Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by RT-PCR. The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains excluding co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Moderate or Severe AGE Occurring &gt;7 Days After Dosing Due to Any Norovirus Strain (Including Co-infection)</measure>
    <time_frame>Up to Day 47</time_frame>
    <description>Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by RT-PCR. The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains including co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Moderate or Severe AGE Occurring &gt;7 Days After Dosing Due to GI.1 or GII.4 Norovirus Strains (Including Co-infection)</measure>
    <time_frame>Up to Day 47</time_frame>
    <description>Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by RT-PCR. The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains including co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4748</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NoV placebo-matching 0.5 mL solution for injection, intramuscularly (IM), once, on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NoV GI.1/GII.4 Bivalent VLP Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NoV GI.1/GII.4 bivalent virus-like particle (VLP) vaccine, 0.5 mL injection, intramuscularly (IM), once, on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NoV Placebo-matching Saline</intervention_name>
    <description>NoV placebo-matching saline (0.9% sodium chloride).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NoV GI.1/GII.4 Bivalent VLP Vaccine</intervention_name>
    <description>NoV bivalent VLP vaccine, adjuvanted with 500 Âµg aluminum as Al(OH)3.</description>
    <arm_group_label>NoV GI.1/GII.4 Bivalent VLP Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant signs and dates a written, informed consent form and any required privacy&#xD;
             authorization prior to the initiation of any trial procedures after the nature of the&#xD;
             trial has been explained according to local regulatory requirements.&#xD;
&#xD;
          2. Male or female participants, 18 to 49 years of age.&#xD;
&#xD;
          3. Is in good health at the time of entry into the trial as determined by medical history&#xD;
             and the clinical judgment of the investigator.&#xD;
&#xD;
          4. Can comply with trial procedures and are available for the duration of follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy.&#xD;
&#xD;
          2. Has known hypersensitivity to any of the Norovirus (NoV) GI.1/GII.4 bivalent&#xD;
             virus-like particle (VLP) vaccine components (including excipients).&#xD;
&#xD;
          3. Has known hypersensitivity or allergy to any of the licensed required concomitant&#xD;
             vaccine components to be administered (including excipients of these vaccines).&#xD;
&#xD;
          4. Has any condition or circumstance that the investigator determines would interfere&#xD;
             with trial evaluation or interpretation.&#xD;
&#xD;
          5. Has known or suspected impairment or alteration of immune function.&#xD;
&#xD;
          6. Has a history of acute gastroenteritis (AGE) within 14 days of enrollment.&#xD;
&#xD;
          7. Has a history of body temperature of 38.0Â°C (100.4Â°F) or higher within 3 days of&#xD;
             intended trial vaccination.&#xD;
&#xD;
          8. Has received blood, blood products, and/or plasma derivatives or any parenteral&#xD;
             immunoglobulin antibody preparation in the past 3 months.&#xD;
&#xD;
          9. Immunosuppressive therapy within 3 months or systemic (e.g., oral or parenteral)&#xD;
             corticosteroid treatment within 60 days prior to investigational trial dose&#xD;
             administration.&#xD;
&#xD;
         10. Is participating in any clinical trial with another investigational product 30 days&#xD;
             prior to the first trial visit or intending to participate in another clinical trial&#xD;
             at any time during the conduct of this trial.&#xD;
&#xD;
         11. Participants who are first-degree relatives of individuals involved in the conduct of&#xD;
             the trial.&#xD;
&#xD;
         12. Has any history of progressive or severe neurologic disorder, seizure disorder or&#xD;
             neuro-inflammatory disease (e.g. Guillain-BarrÃ© syndrome).&#xD;
&#xD;
         13. Has history or any illness that, in the opinion of the investigator, might interfere&#xD;
             with the results of the trial or pose additional risk to the participants due to&#xD;
             participation in the trial.&#xD;
&#xD;
         14. Has received any other vaccines within 14 days (for inactivated vaccines) or 28 days&#xD;
             (for live vaccines) prior to enrollment in this trial with the exception of routine&#xD;
             immunizations as per Military Procedures.&#xD;
&#xD;
         15. If female of childbearing potential, sexually active, and has not used any of the&#xD;
             &quot;acceptable contraceptive methods&quot; for at least 2 months prior to trial entry:&#xD;
&#xD;
               1. Of childbearing potential is defined as status post onset of menarche and not&#xD;
                  meeting any of the following conditions: menopausal for at least 2 years, status&#xD;
                  after bilateral tubal ligation for at least 1 year, status after bilateral&#xD;
                  oophorectomy, or status after hysterectomy.&#xD;
&#xD;
               2. Acceptable birth control methods are defined as one or more of the following:&#xD;
&#xD;
                    -  Hormonal contraceptive (such as oral, injection, transdermal patch, implant,&#xD;
                       cervical ring).&#xD;
&#xD;
                    -  Barrier (condom with spermicide or diaphragm with spermicide) each and every&#xD;
                       time during intercourse.&#xD;
&#xD;
                    -  Intrauterine device (IUD).&#xD;
&#xD;
                    -  Monogamous relationship with vasectomized partner. Partner must have been&#xD;
                       vasectomized for at least six months prior to the participants' trial entry.&#xD;
&#xD;
         16. If female of childbearing potential and sexually active, refusal to use an &quot;acceptable&#xD;
             contraceptive method&quot; from Day 1 through 6 months after the last dose of trial&#xD;
             vaccine. In addition, they must be advised not to donate ova during this period.&#xD;
&#xD;
         17. Has any positive or indeterminate pregnancy test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Great Lakes Naval Station</name>
      <address>
        <city>Great Lakes</city>
        <state>Illinois</state>
        <zip>60088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 27, 2016</study_first_submitted>
  <study_first_submitted_qc>January 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <results_first_submitted>May 14, 2021</results_first_submitted>
  <results_first_submitted_qc>May 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 10, 2021</results_first_posted>
  <disposition_first_submitted>May 30, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>May 30, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 5, 2019</disposition_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02669121/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02669121/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at a single investigative site in the United States from 14 June 2016 to 16 June 2018.</recruitment_details>
      <pre_assignment_details>Healthy volunteers were enrolled in the study and randomized in 1:1 ratio to receive Norovirus GI.1/GII.4 Bivalent VLP Vaccine or Placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>NoV placebo-matching 0.5 mL solution for injection, intramuscularly (IM), once, on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>NoV GI.1/GII.4 Bivalent VLP Vaccine</title>
          <description>NoV GI.1/GII.4 bivalent virus-like particle (VLP) vaccine, 0.5 mL injection, intramuscularly (IM), once, on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2377"/>
                <participants group_id="P2" count="2371"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated (Safety Analysis Set)</title>
              <participants_list>
                <participants group_id="P1" count="2357"/>
                <participants group_id="P2" count="2355"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2087"/>
                <participants group_id="P2" count="2089"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="290"/>
                <participants group_id="P2" count="282"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="140"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discharged from US Military Active Service</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized Set included all enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>NoV placebo-matching 0.5 mL solution for injection, IM, once, on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>NoV GI.1/GII.4 Bivalent VLP Vaccine</title>
          <description>NoV GI.1/GII.4 bivalent VLP vaccine, 0.5 mL injection, IM, once, on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2377"/>
            <count group_id="B2" value="2371"/>
            <count group_id="B3" value="4748"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.3" spread="2.95"/>
                    <measurement group_id="B2" value="20.2" spread="2.74"/>
                    <measurement group_id="B3" value="20.3" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="423"/>
                    <measurement group_id="B2" value="437"/>
                    <measurement group_id="B3" value="860"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1954"/>
                    <measurement group_id="B2" value="1934"/>
                    <measurement group_id="B3" value="3888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="521"/>
                    <measurement group_id="B2" value="484"/>
                    <measurement group_id="B3" value="1005"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1856"/>
                    <measurement group_id="B2" value="1887"/>
                    <measurement group_id="B3" value="3743"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="351"/>
                    <measurement group_id="B2" value="355"/>
                    <measurement group_id="B3" value="706"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1668"/>
                    <measurement group_id="B2" value="1667"/>
                    <measurement group_id="B3" value="3335"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="311"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2377"/>
                    <measurement group_id="B2" value="2371"/>
                    <measurement group_id="B3" value="4748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Moderate or Severe Acute Gastroenteritis (AGE) Occurring for &gt;7 Days After Dosing Due to GI.1 or GII.4 Norovirus Strains (Excluding Co-infection)</title>
        <description>Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by reverse transcriptase polymerase chain reaction (RT-PCR). The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains excluding co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.</description>
        <time_frame>Up to Day 47</time_frame>
        <population>Full Analysis Set included all participants who were randomized and received the trial dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>NoV placebo-matching 0.5 mL solution for injection, IM, once, on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>NoV GI.1/GII.4 Bivalent VLP Vaccine</title>
            <description>NoV GI.1/GII.4 bivalent VLP vaccine, 0.5 mL injection, IM, once, on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Moderate or Severe Acute Gastroenteritis (AGE) Occurring for &gt;7 Days After Dosing Due to GI.1 or GII.4 Norovirus Strains (Excluding Co-infection)</title>
          <description>Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by reverse transcriptase polymerase chain reaction (RT-PCR). The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains excluding co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.</description>
          <population>Full Analysis Set included all participants who were randomized and received the trial dose.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2357"/>
                <count group_id="O2" value="2355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.800</param_value>
            <ci_percent>99.99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.181</ci_lower_limit>
            <ci_upper_limit>0.997</ci_upper_limit>
            <other_analysis_desc>The vaccine efficacy was met if lower bound of confidence interval (CI) for vaccine efficacy was above 0. Vaccine efficacy (VE) was defined as 1-(hazard rate for NoV vaccine arm / hazard rate for placebo arm), where the hazard ratio is from the Cox proportional hazard (PH) model. The 99.99% CI for the VE was obtained by taking 1 minus the 99.99% CI of the hazard ratio from the PH model.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Moderate or Severe AGE Occurring &gt;7 Days After Dosing Due to Any Norovirus Strain (Excluding Co-infection)</title>
        <description>Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by RT-PCR. The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains excluding co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.</description>
        <time_frame>Up to Day 47</time_frame>
        <population>Full Analysis Set included all participants who were randomized and received the trial dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>NoV placebo-matching 0.5 mL solution for injection, IM, once, on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>NoV GI.1/GII.4 Bivalent VLP Vaccine</title>
            <description>NoV GI.1/GII.4 bivalent VLP vaccine, 0.5 mL injection, IM, once, on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Moderate or Severe AGE Occurring &gt;7 Days After Dosing Due to Any Norovirus Strain (Excluding Co-infection)</title>
          <description>Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by RT-PCR. The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains excluding co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.</description>
          <population>Full Analysis Set included all participants who were randomized and received the trial dose.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2357"/>
                <count group_id="O2" value="2355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.618</param_value>
            <ci_percent>95.01</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.208</ci_lower_limit>
            <ci_upper_limit>0.816</ci_upper_limit>
            <other_analysis_desc>The vaccine efficacy was met if lower bound of CI for vaccine efficacy was above 0. Vaccine efficacy (VE) was defined as 1-(hazard rate for NoV vaccine arm / hazard rate for placebo arm), where the hazard ratio is from the PH model. The 95.01% CI for the VE was obtained by taking 1 minus the 95.01% CI of the hazard ratio from the PH model.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Moderate or Severe AGE Occurring &gt;7 Days After Dosing Due to Any Norovirus Strain (Including Co-infection)</title>
        <description>Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by RT-PCR. The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains including co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.</description>
        <time_frame>Up to Day 47</time_frame>
        <population>Full Analysis Set included all participants who were randomized and received the trial dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>NoV placebo-matching 0.5 mL solution for injection, IM, once, on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>NoV GI.1/GII.4 Bivalent VLP Vaccine</title>
            <description>NoV GI.1/GII.4 bivalent VLP vaccine, 0.5 mL injection, IM, once, on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Moderate or Severe AGE Occurring &gt;7 Days After Dosing Due to Any Norovirus Strain (Including Co-infection)</title>
          <description>Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by RT-PCR. The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains including co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.</description>
          <population>Full Analysis Set included all participants who were randomized and received the trial dose.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2357"/>
                <count group_id="O2" value="2355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.618</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.208</ci_lower_limit>
            <ci_upper_limit>0.816</ci_upper_limit>
            <other_analysis_desc>The vaccine efficacy was met if lower bound of CI for vaccine efficacy was above 0. Vaccine efficacy (VE) was defined as 1-(hazard rate for NoV vaccine arm / hazard rate for placebo arm), where the hazard ratio is from the PH model. The 95% CI for the VE was obtained by taking 1 minus the 95% CI of the hazard ratio from the PH model.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Moderate or Severe AGE Occurring &gt;7 Days After Dosing Due to GI.1 or GII.4 Norovirus Strains (Including Co-infection)</title>
        <description>Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by RT-PCR. The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains including co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.</description>
        <time_frame>Up to Day 47</time_frame>
        <population>Full Analysis Set included all participants who were randomized and received the trial dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>NoV placebo-matching 0.5 mL solution for injection, IM, once, on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>NoV GI.1/GII.4 Bivalent VLP Vaccine</title>
            <description>NoV GI.1/GII.4 bivalent VLP vaccine, 0.5 mL injection, IM, once, on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Moderate or Severe AGE Occurring &gt;7 Days After Dosing Due to GI.1 or GII.4 Norovirus Strains (Including Co-infection)</title>
          <description>Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by RT-PCR. The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains including co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.</description>
          <population>Full Analysis Set included all participants who were randomized and received the trial dose.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2357"/>
                <count group_id="O2" value="2355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.800</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.711</ci_lower_limit>
            <ci_upper_limit>0.977</ci_upper_limit>
            <other_analysis_desc>The vaccine efficacy was met if lower bound of CI for vaccine efficacy was above 0. Vaccine efficacy (VE) was defined as 1-(hazard rate for NoV vaccine arm / hazard rate for placebo arm), where the hazard ratio is from the PH model. The 95% CI for the VE was obtained by taking 1 minus the 95% CI of the hazard ratio from the PH model.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Day 1 up to the end of the study (Up to 47 days)</time_frame>
      <desc>At each visit investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by participant or observed by investigator was recorded, irrespective of relation to study treatment. Safety Analysis Set included all participants who received trial dose (NoV GI.1/GII.4 bivalent VLP vaccine or saline placebo).</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>NoV placebo-matching 0.5 mL solution for injection, IM, once, on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>NoV GI.1/GII.4 Bivalent VLP Vaccine</title>
          <description>NoV GI.1/GII.4 bivalent VLP vaccine, 0.5 mL injection, IM, once, on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0 Mixed</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="2355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Gastroenteritis clostridial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Tonsillitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Persistent depressive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2355"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2355"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 21.0 Mixed</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="2355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="2355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="2357"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="2355"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>TrialDisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

